A Phase 2 interventional study of Caspofungin in Liver Transplantation and Fungal Infection, sponsored by Grupo de Estudio de Infecciones en Transplantados. Status unknown at 13 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-04-13.
Sponsored by Grupo de Estudio de Infecciones en Transplantados · Phase 2, Interventional, and Prevention
This is a non-comparative, open, multisite prospective estimation study to evaluate the efficacy and safety of caspofungin in the prophylactic treatment of adults who have received an orthotopic liver transplant and are at high risk of developing an invasive fungal infection. It is expected that the proportion of high-risk liver transplant recipients who develop a documented (proven or probable per European Organization for Research and Treatment of Cancer/Mycoses Study Group [EORTC/MSG] modified criteria) invasive fungal infection during the first 100 days after the onset of prophylaxis with caspofungin will be lower than 15%. It is also expected that the incidence of serious drug-related adverse events will be less than 25%.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 70 is below the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →This is the only study on the registry with Grupo de Estudio de Infecciones en Transplantados as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Absence of breakthrough proven/probable invasive fungal infection by day +100
Absence of breakthrough proven/probable invasive aspergillosis by day +100
Discontinuation of study therapy due to a drug-related adverse event
Incidence of drug-related serious adverse event(s)
Incidence of drug-related adverse event(s)
This study is status unknown, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.